Engineered immune cells take on rare Muscle-Weakening disease
NCT ID NCT06371040
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 28 times
Summary
This early-stage study tests a new treatment called CD19-BCMA CAR-T for people with refractory generalized myasthenia gravis, a condition where the immune system attacks nerve-muscle connections, causing severe weakness. The therapy uses a patient's own immune cells, modified to target and destroy faulty immune cells. The main goal is to find a safe dose and check for side effects in about 9 to 12 adults.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tangdu Hospital, The Fourth Military Medical University
RECRUITINGXi'an, Shaanxi, 710038, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.